Abstract 3: Administration of Injectable Oxygen Suspension Rapidly Reverses Hypoxemia via Intravenous or Intraosseous Route
Introduction. Hypoxemia contributes to cellular dysfunction and death in a number of critical illness states. We investigated the possibility of rapidly reversing severe hypoxemia using intravenous and intraosseous infusions of lipid-based oxygen microparticles (LOMs).
Hypothesis. Arterial oxygen tensions will increase during administration of LOMs via the intravenous or intraosseous route in a rabbit model of hypoxic ventilation.
Methods. We manufactured LOMs from a lipid-based solution and oxygen gas. LOM diameter was determined by light scatter and oxygen content was determined by weight differential of a set volume of suspension. Adult New Zealand rabbits were anesthetized, paralyzed and mechanically ventilated. We placed venous, arterial and intraosseous lines. Hypoxemia was induced by ventilation with 10% oxygen. Following observation for 2 minutes, infusions of LOMs were administered at varying rates over a 2 minute period via either intravenous (n=5) or intraosseous line (n=9), followed by a 1 minute observation period. Endpoints included oxyhemoglobin saturations by pulse oximetry and arterial blood gas values drawn every 30 seconds. Endpoints during infusions were compared over time using a Friedman test.
Results. LOM suspensions contained 52.8±3.0 mL of oxygen gas per dL of suspension. Mean particle diameter was 6.42 microns. Oxyhemoglobin saturation by pulse oximeter rose rapidly in a dose-dependent fashion in both intravenous and intraosseous infusions (Fig A). Relative to baseline measures, arterial PO2 (Fig B) and oxyhemoglobin saturation by co-oximeter (Fig C) increased during both IV and IO infusions (PaO2 p<0.0001 IO; SaO2 p<0.05 IV, p<0.0001 IO). There was a non-significant trend that the increase in oxyhemoglobin saturations was delayed in intraosseous infusions relative to intravenous infusions.
Conclusion. Oxyhemoglobin saturation and oxygen tension can be acutely raised by intravenous or intraosseous infusion of LOMs.
- © 2011 by American Heart Association, Inc.